VA's FY2025 Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for Over $1 Billion

Contract Overview

Contract Amount: $1,047,972,072 ($1.0B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2024-10-01

End Date: 2024-10-31

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 OCTOBER

Plain-Language Summary

Department of Veterans Affairs obligated $1.05 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 OCTOBER Key points: 1. The Department of Veterans Affairs (VA) awarded a significant contract for pharmaceutical prime vendor services. 2. McKesson Corporation, a major player in pharmaceutical distribution, secured this substantial contract. 3. The contract value exceeds $1 billion, indicating a critical need for pharmaceutical supply chain management within the VA. 4. This award highlights the ongoing reliance on established vendors for essential healthcare supplies.

Value Assessment

Rating: good

This contract represents a significant portion of the VA's pharmaceutical spending. Benchmarking against similar large-scale prime vendor contracts is challenging due to the specialized nature of government healthcare procurement, but the value suggests competitive pricing was likely a key factor.

Cost Per Unit: N/A

Competition Analysis

Competition Level: unknown

The contract type is a Delivery Order, suggesting it may be part of a larger indefinite-delivery/indefinite-quantity (IDIQ) contract or a competitive process for a specific period. The method of competition and its impact on price discovery are not detailed here, but large contracts often involve robust evaluation criteria.

Taxpayer Impact: The efficient procurement of pharmaceuticals through this contract is crucial for ensuring veterans receive necessary medications, thereby optimizing taxpayer investment in healthcare services.

Public Impact

Ensures timely access to a wide range of pharmaceuticals for veterans nationwide. Supports the VA's mission to provide comprehensive healthcare services. Contributes to the stability of the pharmaceutical supply chain for federal healthcare facilities. Potentially impacts drug pricing and availability across the VA system.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Lack of detailed competition information.
  • Potential for price fluctuations in pharmaceutical markets.
  • Dependence on a single vendor for a critical service.

Positive Signals

  • Award to a well-established and experienced vendor.
  • Significant investment in veteran healthcare.
  • Potential for economies of scale in procurement.

Sector Analysis

The healthcare sector, particularly pharmaceutical distribution, is characterized by high volume and complex logistics. Government contracts like this are essential for ensuring access to medications for large populations, often involving significant dollar values and long-term vendor relationships.

Small Business Impact

This contract appears to be awarded to a large corporation, McKesson. There is no immediate indication of specific provisions or subcontracting opportunities for small businesses within this express report, which is common for large prime vendor agreements.

Oversight & Accountability

Oversight of this contract will be critical to ensure McKesson meets performance standards, maintains drug availability, and adheres to pricing regulations. The VA's contracting office and program managers will be responsible for monitoring compliance and addressing any issues.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Potential for market concentration and limited competition in future renewals.
  • Vulnerability to pharmaceutical supply chain disruptions.
  • Risk of price increases if market conditions change unfavorably.
  • Dependence on a single entity for a critical national healthcare function.

Tags

department-of-veterans-affairs, delivery-order, billion-dollar

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.05 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 OCTOBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.05 billion.

What is the period of performance?

Start: 2024-10-01. End: 2024-10-31.

What specific metrics are used to evaluate McKesson's performance under this contract, and how are these monitored?

Performance is typically evaluated based on delivery timeliness, order accuracy, drug availability, and adherence to contractual terms. The VA likely employs a performance management plan with defined metrics and regular reporting requirements. Contract officers and subject matter experts would monitor these metrics, conducting periodic reviews and addressing any deviations or performance shortfalls through established communication channels and potential corrective actions.

How does the VA ensure cost-effectiveness and prevent potential price gouging given the large contract value and McKesson's market position?

The VA likely leverages competitive bidding processes, established pricing agreements (e.g., Federal Supply Schedule), and volume discounts to ensure cost-effectiveness. Contract terms may include price reduction clauses and require adherence to established pricing benchmarks. Regular audits and market analysis help identify any significant price deviations, allowing the VA to negotiate or take corrective action to protect taxpayer interests.

What contingency plans are in place if McKesson faces supply chain disruptions or fails to meet delivery obligations?

Contingency planning typically involves identifying alternative suppliers or distribution channels, though this is challenging for prime vendor contracts. The contract likely includes clauses for remedies in case of non-performance, such as penalties or the right to terminate. The VA may also maintain strategic pharmaceutical reserves or have agreements with other vendors to mitigate immediate shortages during critical disruptions.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending